China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on the transfer of rights related to HealZen’s self-developed small-molecule central nervous system (CNS) programs. According to the agreement, NeuShen will secure global exclusive development, regulatory, and commercialization rights to the program, which includes indications for epilepsy, emotional disorders, and more. HealZen Therapeutics will receive an undisclosed amount in upfront and research and development (R&D) milestone payments from NeuShen.
HealZen Therapeutics’ Commitment to Oncology, Autoimmune, and CNS Diseases
HealZen Therapeutics, dedicated to the treatment of oncology, autoimmune, and CNS diseases, boasts an in-house developed DaMLib class drug fragment library, protein degradation drug DaTProD, and protein rescue drug DaTProS technology platforms. These platforms highlight the company’s expertise in developing novel therapies for CNS conditions.
NeuShen’s CNS Expertise and Innovation
NeuShen, a CNS specialist with a presence in Shanghai and Boston, is centered around an innovative discovery engine for AAV-based gene therapies and small molecule drug therapies. The company’s focus on CNS treatments aligns with its mission to acquire and advance cutting-edge therapies to address unmet medical needs in this field.-Fineline Info & Tech
